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information for patients over age 65 with at least one diagnosis for Crohn’s dis-
ease. Patients who initiated therapy with tumor necrosis factor (TNF) and non-
TNF agents were identified. We examined the treatment patterns such as
switching to another TNF, switching to a non-TNF, and discontinuation for two
years after the initiation of TNF biologics. We created a data visualization tool
help visualize how patients change their treatment patterns after first and sec-
ond switches. RESULTS: A total of 3287 Crohn’s disease patients initiated therapy
with a TNF medication. 4.23% of these patients switched to another TNF, 1.00%
switched to a non-TNF, 60.42% discontinued therapy and 34.35% continued
their initial therapy. Among patients who switched to another TNF, 48.20%
continued the switched therapy, 41.01% discontinued, 10.07% switched to an-
other TNF, and 0.72% switched to a non-TNF. A total of 2,140 Crohn’s disease
patients initiated their therapy with a non-TNF, of which 0.89% switched to an
anti-TNF, 0.37% switched to a TNF, 97.38% discontinued therapy, and 1.36%
continued their initial therapy. CONCLUSIONS: When analyzing subsequent
years and switches, treatment patterns can be difficult to capture. Data visual-
ization tools can help present these complicated flows effectively for a diverse
health outcomes research audience.
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OBJECTIVES: Somepatients on prescription proton pump inhibitors (PPIs) continue
to experience breakthrough gastroesophageal reflux disease (GERD) symptoms and
use supplemental over the counter (OTC)medications. This study aimed to identify
factors associatedwith experience of breakthrough symptoms andOTCuse among
prescription PPI users. METHODS: A patient/physician survey and chart review
was conducted in GERD patients currently taking a prescription PPI. Patient [age,
gender, race, body mass index (BMI)], GERD (current severity, years since diagno-
sis), and PPI (directions to take 30-60 minutes prior to eating, daily dose, dosing
frequency) characteristics in addition to self-reported patient behaviors [actually
taking PPIs 30-60 minutes prior to eating; count of missed doses, and doses taken,
but not taken according to directions out of last 10) were considered for model
selection for OTC use and breakthrough symptoms. RESULTS: A total of 501 pa-
tients with mean age 51 years, 37% male, 81% Caucasian, 38% with college degree,
and 16% erosive versus 56% nonerosive GERD (28% undocumented) were enrolled
in the study. Overall, 40%ofpatients reported takinganOTCmedication inaddition to
their PPI. While experiencing breakthrough symptoms was the only significant pre-
dictor of OTC use (OR 5.53, p0.001), nonadherence to directions was associated with
a 14% increase in likelihood of OTC use (p0.07). Seventy-three percent of patients
reported experiencing1 breakthrough symptom. Overweight (OR/CI: 0.50/0.29-0.86)
and obese (OR/CI: 0.57/ 0.34-0.96) patients were less likely to report breakthrough
symptoms compared to normal/underweight patients, while a 1 unit increase in
missed doses was associated with a 41% increased likelihood of breakthrough symp-
toms.Nonadherence todirectionsand timesincediagnosisweresignificantpredictors
inbivariate comparisons, but lost significance in logisticmodels.CONCLUSIONS:This
study suggests real-world patient-reported medication adherence may be associ-
ated with fewer breakthrough symptoms. This highlights the importance and the
impact of medication-taking behavior on patient outcomes.
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OBJECTIVES: Published evidence on the prevalence of non-steroidal anti-inflam-
matory drug (NSAID) and gastroprotective agent (GPA) use in the United States (US)
is lacking. We examined the prevalence of GPA use among arthritis patients using
NSAIDs.METHODS: Aweb-based community panel of men and women age40 in
theUnited Stateswith self-reported arthritiswas invited via e-mail to participate in
a web-based survey. Panelists interested in participating provided consent and
completed the survey. Only participantswho reported using anNSAID in the last 30
days were eligible. Questions regarding NSAID and GPA use (medication/dosage/
frequency/duration of use) were asked, as were comorbid conditions, gastrointes-
tinal history, and other risk factors. RESULTS: Two thousand met the inclusion
criteria and completed the survey (54% response rate). Themajority of participants
had osteoarthritis (n1525, 76%), 354 (18%) had rheumatoid arthritis, and 121 (6%)
had both. Mean age was 62.0 years; 64% were female; 83% were Caucasian; 25%
worked full-time and 39% were retired. The majority (92%) had health insurance,
with half covered by Medicare/Medicaid. Mean time with arthritis was 13.0 years;
47% and 19% experienced arthritis symptoms “daily” and “almost always”, respec-
tively. The most frequently-used NSAIDs were ibuprofen (54%), aspirin (35%) and
naproxen (33%). Nearly 43% reported using a GPA with 86% (n731) reporting use
more often than three times per month. The most frequently-used GPAs were
omeprazole (48%), ranitidine (17%) and esomeprazole (17%). Of daily NSAID users,
42% reported taking a GPA. Of non-GPA users, 12% reported a history of gastro-
esophageal reflux disease, 9% reported a history of ulcers, and 3% reported a his-
tory of gastrointestinal bleeding. CONCLUSIONS: This is the first study in the
United States to document NSAID and GPA use. Importantly, only 42% of daily
NSAID users take GPAs on a routine basis, leaving the majority of NSAID users at
risk for gastrointestinal complications.
GASTROINTESTINAL DISORDERS – Cost Studies
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OBJECTIVES: Dexlansoprazole, a once-daily proton pump inhibitor (PPI) in a Dual
Delayed Release formulation has demonstrated efficacy in a phase 3b study in
maintaining symptom control among gastroesophageal reflux disease (GERD) pa-
tients previously controlled on twice daily (BID) PPIs. A pharmacy budget impact
model (BIM) from a US payer perspective was developed to assess the impact of
switching GERD patients from BID PPIs to QD dexlansoprazole over a three-year
period. METHODS: An excel-based BIM on a hypothetical plan of 1 million mem-
bers was developed. Based on published literature, 28% of members had GERD,
among which 57% were prescribed PPI therapy. Among these, 74%, 23% and 3% of
patientswere onQD, BID and as needed PPI therapy, respectively. The proportion of
patients switching from BID PPI to QD dexlansoprazole and efficacy of dexlanso-
prazole in achieving symptom control among those patientswas assumed to range
from 84%-88% based on the results of the phase 3b trial. Market share of PPIs and
drug costs were derived using internally available data. The market share of dex-
lansoprazole in year 1 was 4.23% and 8.44% pre- and post-switching, respectively.
Model outcomes for years 1, 2 and 3 included: net total and permember per month
(PMPM) pharmacy savings. RESULTS: The net pharmacy saving from switching to
QD dexlansoprazole was estimated to be $7.9, $6.4 & $5.9 million for years 1, 2, & 3,
respectively. PMPM pharmacy cost savings ranged from $0.66 in year 1 to $0.50 in
year 3. The model results were most sensitive to cost of esomeprazole, proportion
of GERD patients on PPI, prevalence of the disease, and proportion of patients
switching from BID esomeprazole to QD dexlansoprazole. CONCLUSIONS: Based
on the economic model, switching GERD patients from twice daily PPIs to QD dex-
lansoprazole may generate cost savings for US health plans.
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OBJECTIVES: Highly effective biologic therapies offer new treatment options for
patients suffering from moderate to severe ulcerative colitis (UC) who fail with
conventional therapies. A budget impact model was constructed to estimate the
costs of infliximab therapy for steroid-dependent, steroid-refractory and acute UC
patients in the perspective of Croatia. METHODS: Using epidemiology data and
medical treatment guidelines, a budget impactmodel was constructed to calculate
the annual cost of infliximab according to the Croatian Guidelines for Treatment of
UC. Moderate to severe UC patients that were diagnosed steroid-dependent, and
acute or steroid-refractory patients that were non-responsive to IV corticosteroids
were considered eligible for infliximab. Clinical trial data was applied to the guide-
lines to determine infliximab eligible patients. Sensitivity analysis was conducted
to describe the ranges of costs by varying incidence, and dosing, considering drug
wastage. RESULTS: According to the epidemiology data, 17.8% (411 patients) of all
UC patients fall into these 3 categories of patients and should be treated with
infliximab. Total costs of treating these patients according to drafted guidelines
would be 33,822,366 kn (0.01% of GDP, 0.13% of total healthcare costs or 0.50% of
total pharmaceutical sales for 2010), 19,329,407 kn (57.15%) of which is attributed to
steroid-dependent patients, 7,893,089 kn (23.34%) to steroid-refractory and
6,599,870 kn (19.51%) to acute patients. New patients who require 8 infusions
within the first year account for 11% of the cost, whereas maintenance therapy
patients receiving 6 infusions explain the rest. Adjusting the dosage from400mg/kg
to 350mg/kg decreases the total cost by 12.50% (4,227,796 kn). A decreasing inci-
dence of UC patients from 5.9 to 3.9 per 100,000 reduces the cost by 4.69% (1,586,046
kn). CONCLUSIONS: Given the significant improvement in quality of life of those
with UC, infliximab should be considered where the budget allows it. Steroid-
refractory UC patients accounted for majority of the costs.
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OBJECTIVES: To evaluate the costs associated with the treatment of Hepatitis C
Virus (HCV) treated with Peg-interferon Alpha-2a versus Peg-Interferon Alpha 2b.
METHODS: For an initial distribution of patients it was used as an assumption that
60% of patients had chronic hepatitis and the other had compensated hepatitis.
With this information was developed a Markovmodel with probabilities of disease
evolution. The stages for thismodel from this were: liver cancer, ascites, refractory
ascites, gastrointestinal bleeding, hepatic encephalopathy, liver transplantation
and death. Costs are expressed in US dollars. RESULTS: The highest response rates
were foundwith Peg-Interferon Alpha-2a for genotypes 1, 2 and 3 with a difference
up to 15% compared to Peg-Interferon Alpha-2b. Due to a higher sustained virolog-
ical response rate with Peg-Interferon Alpha-2a, the percentage of patients using
this treatment had a lower probability of falling and developing chronic complica-
tions of the disease. Therefore, the cost of the disease treatment decreases. Also
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the cost of treatment with Peg-Interferon Alpha-2a is lower compared to Peg-In-
terferon Alpha 2b. For a 10-year projection which simulates through a Markov
model that patients that did not respond to treatment evolved to chronicity of the
disease costs per patient with Peg-interferon Alpha-2a was $ 25,913, while with
Peg-Interferon Alpha-2b was $ 37,352, generating savings of $ 11,439 per patient
who was treated with Peg-interferon Alpha-2a. CONCLUSIONS: The use of Peg-
Interferon Alpha-2a was the dominant alternative because it was the most effec-
tive and least costly to treat HCV.
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OBJECTIVES: TNF antagonists are effective therapy for moderate to severe active
Crohn’s disease (CD). Despite their efficacy, these monoclonal antibodies are asso-
ciated with high treatment costs. The objective was to evaluate the economic
impact of the introduction of anti-TNFs for CD treatment on health care resource
utilization fromahealth care systemperspective.METHODS:A retrospective study
was conducted using a random sample of patients diagnosed with CD (ICD-
9555.x) who initiated adalimumab or infliximab therapy between January 2001
and December 2009. Prescription and medical data from the Régie de l’assurance-
maladie du Québec were also obtained from three samples of age- and gender-
matched controls: 1) general population; 2) CD patients treated neither with anti-
TNFs nor antimetabolites; and 3) CD patients taking only antimetabolites. Health
care resource utilization and costs were estimated for the year preceding and fol-
lowing index date. Disease severity was assessed through prednisone and antime-
tabolite use and healthcare resource utilization in the year before index date.
RESULTS: A cohort of 614 patients was obtained (mean age40.5years, 61% fe-
males). Anti-TNF treated patients’ average cost for health care resources was
CAN$7,202. In comparison, costs in the general population, patients treated neither
with anti-TNFs nor antimetabolites, and patients taking only antimetabolites,were
CAN$1,093, CAN$2,029, and CAN$3,024 respectively. In the year before anti-TNF
initiation, CD patients received more prednisone and antimetabolites and used
more health care resources. Following anti-TNF initiation, the cost of drugs re-
ceived was higher for this cohort, but costs of medical visits, ER visits and hospi-
talizations were significantly lower (CAN$882 vs. CAN$554, CAN$297 vs. CAN$161,
and CAN$5,423 vs. CAN$2,963, respectively, p0.001 for all). CONCLUSIONS: Bio-
logic users are more likely to have severe CD than controls resulting in higher
medical resource consumption and greater prednisone and antimetabolites use.
Initiation of a biologic treatment in these patients is associated with lower health
care resource utilization and cost offsets.
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OBJECTIVES: Several studies show that adherence is an important factor to treat-
ment success, improving patient outcomes and reducing global costs. The aim of
this study is to estimate the clinical and economic impact of non-adherence by
patients with ulcerative colitis in remission that are undermaintenance treatment
with mesalazine in the Brazilian Public Healthcare perspective. METHODS: We
compared two schemes of Mesalazine 2 grams/per day: once daily (2 grams sachet)
or twice daily (two 500 mg capsules q12). We constructed a decision tree analytical
model to compare costs and outcomes of Mesalazine once daily (MOD) with Me-
salazine twice daily (MTD) over 12 months. Treatment pathways described in the
model are based on Brazilian Government Clinic and Therapeutics Guidelines,
therefore, biological drugs were not considered in this analysis, because there are
not reimbursed. In both arms, the failure to maintain remission led to other treat-
ments, as needed: prednisone, cyclosporin, azatioprine and colectomy. Adherence
data was obtained from real life prospective studies (Kane et. al.). Costs considered
were: drug, laboratory and diagnostic tests’ costs, specialist consultation and hos-
pitalization costs (all costs are referred to year 2011). The mains outcomes consid-
ered were colectomy surgery avoided and rates of remission without relapse.
RESULTS: Results of the analysis suggest that the average aggregated treatment
cost per person for all medical interventions at 12 months was lower for MOD
compared with MTD (USD 1924 versus USD 1957). Additionally, there is a trend
towards improved effectiveness with MOD inmaintenance remission of ulcerative
colitis with 6.6% re-inductions and 17.2% colectomy surgeries avoided.
CONCLUSIONS: Results from base-case and sensitivity analysis indicate that MOD
presents lower costs and better effectiveness than MTD from a public payers’ per-
spective in Brazil.
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OBJECTIVES: To compare the all-causemedical resource utilization in chronic liver
disease (CLD) patients with thrombocytopenia (TCP) versus no thrombocytopenia,
using the Veterans health administration (VHA) database. METHODS: All utiliza-
tion records of patients in the VA national patient care databases, who had a
diagnosis of CLD between 1999 and 2008, were followed from the date of CLD
diagnosis to 180 days following the earlier of two events: the last date a platelet
count was available for each patient, or the date of the last platelet count of fewer
than 50,000 cells / L. Platelet counts and outcomes such as, number of physician
visits (PV) and outpatient procedures (OPP), and healthcare costs (HCC) were deter-
mined for every threemonth period up to study end for each eligible patient, using
a longitudinal per patient per 3-month dataset. Generalized linear models (GLMs)
were used to study the impact of change in platelet counts on health care utiliza-
tion and costs, after adjusting for hepatitis C infection and other covariates.
RESULTS: A total of 935 and 256,516 patient-3-month observations were available
for comparing health care use in CLD patientswith TCP versus no TCP respectively.
After adjusting for liver disease severity and other covariates incidence rate ratios
for PV and OPP for an increase in platelet counts by 25,000, were 0.992 (95% CI:
0.990-0.993, p 0.0001) and 0.989 (95% CI: 0.987 – 0.990, p 0.0001) respectively. For
a decrease in platelet counts of 10,000 and 25,000 among observations with a max-
imum platelet count of 50,000 / L during the study period, the average predicted
change in overall health care costs per quarterwas$139 (SD: $379) and$369 (SD:
$1,004), respectively (p  0.0001). CONCLUSIONS: In a VA patient population with
CLD, TCP is associated with modest increase in health care utilization and costs as
compared to no TCP.
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OBJECTIVES: Patients with chronic constipation (CC) are often treated with diverse
over the counter (OTC) laxatives, bulking agents, stool softeners, and a limited
choice of prescription (Rx) drugs. Sub-optimal treatment often results in adverse
medical events or treatmentmodifications. The purpose of this study is to estimate
healthcare resource utilization (HRU) and costs of such unmet treatment needs.
METHODS: Data from the Missouri Medicaid program covering medical services
and Rx andOTCmedications (1997-2010) were used to select adult patientswith CC
receiving constipation treatments. The index date was defined as the date of the
first constipation-treatment claim. Indicators of unmet treatment needs were ob-
served during the one-year period after the index date and defined as the following
events occurring while on constipation treatment: 1) switch to or addition of a new
constipation treatment; 2) constipation-related inpatient (IP) or emergency room
(ER) admission; 3) megacolon or fecal impaction diagnosis; 4) constipation-related
surgery/medical procedure; or 5) use of other unusual constipation treatments.
Incremental HRU and costs (USD 2010; measured from a public-payer perspective)
were compared between patients with and without indicators of unmet needs
using multivariate generalized linear regression models. RESULTS: A total of 8745
patients with CC were identified; 54.9% of them were found to have unmet needs
during the one-year period following the index date. After adjusting for baseline
differences, indicators of unmet needs were associated with more HRU, especially
the number of IP days (IRR 1.54; P0.001) and ER admissions (IRR1.35; P0.001).
Indicators of unmet needs were associated with a $2,978 incremental total annual
healthcare costs (P0.001) compared to patients without indicators of unmet
needs. The cost difference was mainly driven by IP ($2,575 vs. $1,534; P0.001) and
pharmacy ($7,114 vs. $5,929; P0.001) costs. CONCLUSIONS: Unmet treatment
needs among CC patients were associated with a significant economic burden.
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OBJECTIVES: Previous studies demonstrate that diverticulitis (DV) is costly to pay-
ers. Most research focuses on total costs and acute episodes, while the burden of
recurrent episodes is not well documented. This study assessed the direct eco-
nomic burden associated with DV recurrence among managed care enrollees.
METHODS: Data were drawn from insurance claims from 40 US health plans.
Patients with a primary DV diagnosis (ICD-9-CM 562.11 or 562.13) between January
1, 2005 to December 31, 2008 were subjected to the following criteria: antibiotic
treatment 3 days post-diagnosis and 6 months continuous pre- and 12
months post-index date (first observed DV diagnosis) plan enrollment. The first 6
weeks post-index date defined the initial acute episode period. Within a given
6-week period following the acute episode, a recurrent episode was defined by a
DV-related hospitalization or ER visit, or a DV-related office visit with antibiotic
treatment within 3 days of the visit. Those with a recurrence were stratified into
those with and without surgical intervention. Recurrence-related costs (2009 US$)
were evaluated for 12 months post-initial acute episode. RESULTS: A totall 36,636
patients were selected (53% male, mean age 52 years); 16.5% (N6,045) had 1
recurrence. Among those with 1 recurrence, the mean number (SD) of recur-
rences was 1.3 (0.6), while the total cost of all recurrences was 4 times the initial
acute episode cost ($12,806 vs. $3,132). For the surgical group (N2868), the differ-
ence between the total cost of all recurrences and initial acute episode costwas still
A137V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) A 1 – A 2 5 6
